Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study

Sponsor: Universiti Sains Malaysia
Study ID: NCT02342392
Phase: PHASE2/PHASE3
Status: Completed

Conditions

Pterygium

Eligibility Criteria

Sex: ALL
Age: N/A - N/A
Healthy Volunteers: Not accepted

Interventions

ranibizumab — DRUG
Intralesional ranibizumab 0.3 mg/0.03mL injected 1 week before pterygium excision surgery.

Study Details

The purpose of this study is to evaluate the pterygium vascularity and size before and after intralesional ranibizumab injection and to evaluate its recurrence rate following pterygium excision surgery.

Key Dates

First listed: Jan 19, 2015
Start date: Sep 30, 2012
Status verified: Jan 2015
Primary completion: Sep 30, 2014
Completion: Sep 30, 2014

Study Design

Enrollment: 36 participants (actual)
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Arms

Active Comparator: treatment group
intralesional ranibizumab injected
No Intervention: control group
no intralesional ranibizumab injected.

Primary Outcome Measure

pterygium recurrence [ Time Frame: 1 year ]